Which Indian ADRs Are Shining Despite the Country's Slowdown?

Check out Infosys, Dr. Reddy's Laboratories, and Wipro. You'll be surprised.

Feb 7, 2014 at 3:59PM

India, like most emerging markets, has started to make a strong correction after the U.S. Federal Reserve began drawing down its stimulative long-term asset purchases. Money is flowing away from the country, seeking refuge in developed countries. As a response, the Indian rupee has declined about 14% in the past year, adding to price pressures by raising the cost of imports in the country. The outlook is not the best for the country, as the latest measures taken by the Indian Central Bank -- tighter monetary policy and interest rate increases -- will probably contract the economy.

However, these three companies are enjoying good momentum. Find out why.

Reverting bad trends
First, here's a leading Indian provider of business consulting, technology, engineering, and outsourcing services: Infosys (NYSE:INFY).

Third-quarter results gave investors a surprise, as earnings per share reversed a multiquarter downtrend, rising 3.8% year over year. Plus, after showing consecutive declines in margins throughout the past six quarters, Infosys is finally showing margin growth.

The company is also posting good profits and winning Fortune 500 clients. In fact, this last quarter Infosys managed to book 54 new clients, with 26 of them signing deals upward of $1 million -- not bad at all. The company's big data and cloud offerings are serving as a key catalyst driving growth. Sales rose to $2.1 billion in the quarter, up 9.9% from the year-ago period.

In addition, India only represented 2.6% of revenue in 2013, so the devaluation of the rupee could only be beneficial for Infosys, as it helps the company earn hard currency while it pays salaries and other costs in rupees.

Impressive international sales growth
Second, here's Dr. Reddy's Laboratories (NYSE:RDY), which is a low-cost manufacturer of generic drugs.

The positive currency effects from depreciation in the rupee are also helping Dr. Reddy's, leading to a strong Q2 2014. Total revenue climbed 17%, with a 32% increase in generic segment revenue. North America sales grew 43% thanks to new generic-drug launches and market share gains for some drugs.

Overall, the context in India is helping Dr. Reddy's. Gross margin is at 58% thanks to product mix and the currency effects. Domestic generic sales are only up about 8%, and the recent government pricing regulation will keep this market constrained. But hey, other combined emerging markets witnessed 42% growth.

Well positioned
Finally, you have to take a look at Wipro (NYSE:WIT), one of the largest India-based global IT services providers.

Third-quarter results were also ahead of expectations for Wipro, as the company experienced solid performance across all service lines. Net income from continuing operations reached $325 million, up 27% year over year.

The IT spending environment continues to show improvements, and Wipro added 42 new customers in the quarter, boosting its pipeline. The company has managed to build a niche in some emerging IT services, which should help Wipro stay ahead of the competition.

The company is not sealed off from the effects of a slowdown, but its focus on research and development services, which account for 10% of revenue, should help it withstand some impact, given that these services do not normally fall under clients' discretionary budgets. During the 2009 crisis, the company fared better than its peers thanks to its breadth of services and geographic reach.

Bottom line
Given the context, these three companies seem like great investing opportunities, and right now there's no apparent reason for a change in their growth trends.

Infosys is in good shape and showing healthy growth. Because its sales are mostly limited to America and Europe, only a slowdown in these regions could affect the stock.

Dr. Reddy's is in a similar situation, and its outlook is very promising. Pay attention to the company's market share and sales growth.

Regarding Wipro, its competitive edge and the company's long-term fundamentals remain intact. It is a good stock to own.

3 "Set It and Forget It Stocks"
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal "The Motley Fool's 3 Stocks to Own Forever." These picks are free today! Just click here now to uncover the three companies we love. 

Louie Grint has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers